Form 4: Madrigal Pharmaceuticals Director Fred B. Craves Reports Stock Transactions

Director Fred B. Craves reports multiple transactions involving Madrigal Pharmaceuticals stock, including acquisitions via option exercises and sales at prices ranging from approximately $322 to $335.

Summary

• On March 12 and 13, 2025, Fred B. Craves, a director of Madrigal Pharmaceuticals, engaged in multiple transactions involving the company's common stock.
• These transactions included the exercise of stock options at prices of $65.06 and $111.06, resulting in the acquisition of 1,728 and 6,000 shares respectively on March 12, and 7,742 shares on March 13.
• Craves also sold shares on both days at varying prices, ranging from $330.00 to $334.99 on March 12 and $322.02 to $330.22 on March 13.
• The sales were executed in multiple transactions at weighted average prices.
• Following these transactions, Craves directly owns 350,076 shares of common stock.
• He also indirectly owns 11,210 shares through a grantor retained annuity trust, 1,261 shares through Bay City Capital LLC, and 21,000 shares through the Craves Family Foundation.

Sentiment

Score: 5

Explanation: The document is a standard regulatory filing detailing stock transactions. It doesn't inherently convey positive or negative sentiment, but rather provides factual information.

Industry Context

This filing is a routine disclosure of stock transactions by a company insider, as required by the SEC. It provides transparency into the trading activities of key personnel and their holdings in the company.

Stakeholder Impact

• Shareholders may be interested in the trading activity of company insiders as it can provide insights into management's perspective on the company's value and prospects.

Key Dates